Restenosis trial to begin in October:
This article was originally published in Clinica
Spectranetics has said it hopes to begin its in-stent restenosis clinical trial in October and has appointed Duke Clinical Research Institute as the trial co-ordination centre. The trial will assess Spectranetics' CVX-300 excimer laser coronary angioplasty system with angioplasty versus angioplasty alone on patients with blocked stents (see Clinica No 842, p 17).
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.